A

AlloVir

D
ALVR
USD
0.0091
(0.9201%)
Market Closed
4,055.00
Volume
EPS
-
Div Yield
-0.811463
P/E
115,146,087.96
Market Cap
Today
-3.0971%
1 Week
10.226%
1 Month
25.927%
6 Months
25.091%
12 Months
-40.234%
Year To Date
46.844%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
GOOGL
GOOGL
4.3
(2.436%)
USD
AAPL
AAPL
5
(2.2453%)
USD
MSFT
MSFT
5.54
(1.3189%)
USD
S
SNAP
0.297
(2.4384%)
USD
TSLA
TSLA
8.33
(2.8876%)
USD
NVDA
NVDA
3.18
(2.1824%)
USD
Z
ZM
0.54
(0.6778%)
USD
AMZN
AMZN
3.02
(1.4575%)
USD

Title:
AlloVir

Sector:
Healthcare
Industry:
Biotechnology
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.
Do you need help or have a question?
Contact Us